New Bone-Forming Agents

  • Socrates E. PapapoulosEmail author


Pharmacological interventions for patients with osteoporosis aim at decreasing the risk of fractures and associated clinical consequences by correcting the imbalance between bone resorption and bone formation that constitutes the pathophysiological basis of the disease. Despite the availability of efficacious treatments for fracture reduction, there are still unmet needs requiring a broader range of therapeutics. In particular, there is a need for agents capable of replacing already lost bone and of drastically reducing the risk of non-vertebral fractures, the most frequent fragility fractures. In recent years, new molecules and therapeutic targets have been identified, and many were investigated as potential treatments for osteoporosis. This chapter briefly reviews newly developed bone-forming agents.


Osteoporosis Bone resorption Bone formation Fragility fracture Parathyroid hormone (PTH) peptides Sclerostin inhibitors Romosozumab 


  1. 1.
    Appelman-Dijkstra NM, Papapoulos SE. Novel approaches to the treatment of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2014;28:843–57.CrossRefGoogle Scholar
  2. 2.
    Compston JE. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone. 2007;40:1447–52.CrossRefGoogle Scholar
  3. 3.
    Leder BZ, O’Dea LS, Zanchetta JR, et al. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2015;100:697–706.CrossRefGoogle Scholar
  4. 4.
    Miller PD, Hattersly G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316:722–33.CrossRefGoogle Scholar
  5. 5.
    Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL. Sclerostin: current knowledge and future perspectives. Calcif Tissue Int. 2010;87:99–107.CrossRefGoogle Scholar
  6. 6.
    van Lierop AH, Appelman-Dijkstra NM, Papapoulos SE. Sclerostin deficiency in humans. Bone. 2017;96:51–62.CrossRefGoogle Scholar
  7. 7.
    Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6:e25900.CrossRefGoogle Scholar
  8. 8.
    Appelman-Dijkstra NM, Papapoulos SE. Modulating bone resorption and bone formation in opposite directions in the treatment of postmenopausal osteoporosis. Drugs. 2015;75:1049–58.CrossRefGoogle Scholar
  9. 9.
    Appelman-Dijkstra NM, Papapoulos SE. Sclerostin inhibition in the management of osteoporosis. Calcif Tissue Int. 2016;98:370–80.CrossRefGoogle Scholar
  10. 10.
    Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010;25:2647–56.CrossRefGoogle Scholar
  11. 11.
    Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010;25:948–59.CrossRefGoogle Scholar
  12. 12.
    Ominsky MS, Boyce RW, Li X, Ke HZ. Effects of sclerostin antibodies in animal models of osteoporosis. Bone. 2017;96:63–75.CrossRefGoogle Scholar
  13. 13.
    Ominsky MS, Niu QT, Li C, Li X, Ke HZ. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J Bone Miner Res. 2014;29:1424–30.CrossRefGoogle Scholar
  14. 14.
    Papapoulos SE. Anabolic bone therapies in 2014: new bone-forming treatments for osteoporosis. Nat Rev Endocrinol. 2015;11:69–70.CrossRefGoogle Scholar
  15. 15.
    McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412–20.CrossRefGoogle Scholar
  16. 16.
    Genant HK, Engelke K, Bolognese MA, et al. Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res. 2017;32:181–7.CrossRefGoogle Scholar
  17. 17.
    Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390:1585–94.CrossRefGoogle Scholar
  18. 18.
    Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375:1532–43.CrossRefGoogle Scholar
  19. 19.
    Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377:1417–27.CrossRefGoogle Scholar
  20. 20.
    Appelman-Dijkstra NM, Papapoulos SE. Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway. Nat Rev Endocrinol. 2018;14:605–23.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Center for Bone Quality, Leiden University Medical CenterLeidenThe Netherlands

Personalised recommendations